JP2002520273A - 抗うつ効果を有する治療薬 - Google Patents
抗うつ効果を有する治療薬Info
- Publication number
- JP2002520273A JP2002520273A JP2000558802A JP2000558802A JP2002520273A JP 2002520273 A JP2002520273 A JP 2002520273A JP 2000558802 A JP2000558802 A JP 2000558802A JP 2000558802 A JP2000558802 A JP 2000558802A JP 2002520273 A JP2002520273 A JP 2002520273A
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- pramipexole
- tetrahydro
- propylamino
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 15
- 230000001430 anti-depressive effect Effects 0.000 title claims description 12
- 229940124597 therapeutic agent Drugs 0.000 title claims 13
- 229960003089 pramipexole Drugs 0.000 claims abstract description 38
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims abstract description 34
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims abstract description 32
- 229960002073 sertraline Drugs 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- FASDKYOPVNHBLU-UHFFFAOYSA-N N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Chemical compound C1C(NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-UHFFFAOYSA-N 0.000 claims abstract description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000002253 acid Substances 0.000 claims description 13
- 239000000935 antidepressant agent Substances 0.000 claims description 13
- 229940005513 antidepressants Drugs 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 3
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims description 3
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 3
- 229960004538 alprazolam Drugs 0.000 claims description 3
- 229960004782 chlordiazepoxide Drugs 0.000 claims description 3
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004606 clomipramine Drugs 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229960005426 doxepin Drugs 0.000 claims description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 3
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 3
- 229960004038 fluvoxamine Drugs 0.000 claims description 3
- 229960001785 mirtazapine Drugs 0.000 claims description 3
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 3
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004644 moclobemide Drugs 0.000 claims description 3
- 229960001800 nefazodone Drugs 0.000 claims description 3
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 3
- 229960001158 nortriptyline Drugs 0.000 claims description 3
- 229960002296 paroxetine Drugs 0.000 claims description 3
- 229960003991 trazodone Drugs 0.000 claims description 3
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 3
- 229960002431 trimipramine Drugs 0.000 claims description 3
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- 229960004688 venlafaxine Drugs 0.000 claims description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001255 viloxazine Drugs 0.000 claims description 3
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 2
- QPGGEKPRGVJKQB-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-11-methyl-6-benzo[b][1,4]benzodiazepinone Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 claims description 2
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 2
- 229960003075 dibenzepin Drugs 0.000 claims description 2
- 229960002813 lofepramine Drugs 0.000 claims description 2
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004090 maprotiline Drugs 0.000 claims description 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 2
- 229960003955 mianserin Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229960004940 sulpiride Drugs 0.000 claims description 2
- 229950010601 pramipexole dihydrochloride monohydrate Drugs 0.000 claims 4
- QMNWXHSYPXQFSK-KLXURFKVSA-N pramipexole hydrochloride anhydrous Chemical compound Cl.Cl.C1[C@@H](NCCC)CCC2=C1SC(N)=N2 QMNWXHSYPXQFSK-KLXURFKVSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims 1
- YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims 1
- QMNWXHSYPXQFSK-UHFFFAOYSA-N hydron;6-n-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;dichloride Chemical compound Cl.Cl.C1C(NCCC)CCC2=C1SC(N)=N2 QMNWXHSYPXQFSK-UHFFFAOYSA-N 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- GYOABOCBMBUFQN-UHFFFAOYSA-N n-propyl-1,3-benzothiazol-2-amine Chemical compound C1=CC=C2SC(NCCC)=NC2=C1 GYOABOCBMBUFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960005290 opipramol Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229960002652 pramipexole dihydrochloride Drugs 0.000 claims 1
- VQMNWIMYFHHFMC-UHFFFAOYSA-N tert-butyl 4-hydroxyindole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1O VQMNWIMYFHHFMC-UHFFFAOYSA-N 0.000 claims 1
- 229960003741 tranylcypromine Drugs 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- -1 opipramor Chemical compound 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19830201.0 | 1998-07-07 | ||
| DE19830201A DE19830201A1 (de) | 1998-07-07 | 1998-07-07 | Mittel mit antidepressiver Wirkung |
| PCT/EP1999/004595 WO2000002542A2 (de) | 1998-07-07 | 1999-07-02 | Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002520273A true JP2002520273A (ja) | 2002-07-09 |
| JP2002520273A5 JP2002520273A5 (https=) | 2006-08-31 |
Family
ID=7873155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000558802A Pending JP2002520273A (ja) | 1998-07-07 | 1999-07-02 | 抗うつ効果を有する治療薬 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6255329B1 (https=) |
| EP (1) | EP1093369B1 (https=) |
| JP (1) | JP2002520273A (https=) |
| KR (1) | KR100557692B1 (https=) |
| CN (1) | CN1230168C (https=) |
| AR (1) | AR019896A1 (https=) |
| AT (1) | ATE228365T1 (https=) |
| AU (1) | AU762128B2 (https=) |
| BG (1) | BG64972B1 (https=) |
| BR (1) | BR9911768A (https=) |
| CA (1) | CA2336833C (https=) |
| CZ (1) | CZ294087B6 (https=) |
| DE (2) | DE19830201A1 (https=) |
| DK (1) | DK1093369T3 (https=) |
| EA (1) | EA003142B1 (https=) |
| EE (1) | EE04296B1 (https=) |
| ES (1) | ES2183583T3 (https=) |
| HU (1) | HUP0103922A3 (https=) |
| ID (1) | ID27776A (https=) |
| IL (1) | IL140603A0 (https=) |
| MY (1) | MY117969A (https=) |
| NO (1) | NO20010064L (https=) |
| NZ (1) | NZ509729A (https=) |
| PL (1) | PL195043B1 (https=) |
| PT (1) | PT1093369E (https=) |
| RS (1) | RS49795B (https=) |
| SK (1) | SK284923B6 (https=) |
| TR (1) | TR200100146T2 (https=) |
| TW (1) | TW592698B (https=) |
| WO (1) | WO2000002542A2 (https=) |
| YU (1) | YU401A (https=) |
| ZA (1) | ZA200100090B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020516625A (ja) * | 2017-04-10 | 2020-06-11 | チェイス セラピューティクス コーポレイション | Ｎｋ１拮抗薬組み合わせおよびシヌクレイノパチーを治療する方法 |
| JP2020526494A (ja) * | 2017-06-30 | 2020-08-31 | チェイス セラピューティクス コーポレイション | Ｎｋ−１アンタゴニスト組成物およびうつ病の処置における使用法 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006162A1 (de) * | 1998-07-27 | 2000-02-10 | Boehringer Ingelheim Pharma Kg | Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum |
| US20020165246A1 (en) * | 2001-03-05 | 2002-11-07 | Andrew Holman | Administration of sleep restorative agents |
| DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
| ES2432527T3 (es) * | 2001-12-11 | 2013-12-04 | University Of Virginia Patent Foundation | Uso de pramipexol para tratar la esclerosis lateral amiotrófica |
| US20060281797A1 (en) * | 2001-12-11 | 2006-12-14 | University Of Virginia Patent Foundation | Neurorestoration with R(+) Pramipexole |
| DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| WO2005070428A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
| WO2007022182A1 (en) * | 2005-08-15 | 2007-02-22 | University Of Virginia Patent Foundation | Neurorestoration with r(+) pramipexole |
| US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
| ES2379117T3 (es) | 2006-05-16 | 2012-04-20 | Knopp Neurosciences, Inc. | Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas |
| US20080254118A1 (en) * | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
| US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| CA2681110A1 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
| US20080254117A1 (en) * | 2007-04-10 | 2008-10-16 | Noel Cotton | Process for preparing pramipexole dihydrochloride tablets |
| KR20110071064A (ko) * | 2008-08-19 | 2011-06-28 | 크놉 뉴로사이언시스 인코포레이티드 | (ｒ)-프라미펙솔을 사용하는 조성물 및 방법 |
| EP2341912B1 (en) | 2008-09-05 | 2014-01-22 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| JP2012525426A (ja) * | 2009-04-30 | 2012-10-22 | スパーナス ファーマシューティカルズ インコーポレイテッド | うつ病を治療する方法 |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| AU2013217013B2 (en) | 2012-02-08 | 2017-04-20 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| EP3838271B1 (en) | 2013-07-12 | 2025-09-03 | Areteia Therapeutics, Inc. | Treating elevated levels of eosinophils and/or basophils |
| ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
| CA2921381A1 (en) | 2013-08-13 | 2015-02-19 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
| CN110028464B (zh) * | 2019-04-26 | 2022-11-18 | 浙江海洋大学 | 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08504201A (ja) * | 1992-12-05 | 1996-05-07 | ベーリンガー インゲルハイム コマンディトゲゼルシャフト | 抗うつ作用を有する医薬組成物としての２‐アミノ‐６‐ｎ‐プロピル‐アミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールの使用 |
| JPH09110695A (ja) * | 1995-08-15 | 1997-04-28 | Chugai Pharmaceut Co Ltd | 不安神経症治療剤 |
| JPH11506472A (ja) * | 1996-03-29 | 1999-06-08 | ファイザー インク． | ５―ｈｔ１ａおよび／または５―ｈｔ１ｄ受容体の選択的（アンタ）アゴニストとしてのベンジル（イデン）―ラクタム誘導体、その調製法及びその使用法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| ATE45735T1 (de) * | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
| DE3843227A1 (de) * | 1988-12-22 | 1990-07-05 | Boehringer Ingelheim Kg | Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| DE3937271A1 (de) * | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
| US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| ATE282417T1 (de) * | 1996-12-02 | 2004-12-15 | Merck Sharp & Dohme | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen |
| WO1999036064A2 (en) * | 1998-01-13 | 1999-07-22 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
-
1998
- 1998-07-07 DE DE19830201A patent/DE19830201A1/de not_active Withdrawn
-
1999
- 1999-07-02 HU HU0103922A patent/HUP0103922A3/hu unknown
- 1999-07-02 WO PCT/EP1999/004595 patent/WO2000002542A2/de not_active Ceased
- 1999-07-02 PL PL99345842A patent/PL195043B1/pl not_active IP Right Cessation
- 1999-07-02 EA EA200100084A patent/EA003142B1/ru not_active IP Right Cessation
- 1999-07-02 CZ CZ200177A patent/CZ294087B6/cs not_active IP Right Cessation
- 1999-07-02 DE DE59903556T patent/DE59903556D1/de not_active Expired - Fee Related
- 1999-07-02 DK DK99934560T patent/DK1093369T3/da active
- 1999-07-02 RS YUP-4/01A patent/RS49795B/sr unknown
- 1999-07-02 YU YU401A patent/YU401A/sh unknown
- 1999-07-02 IL IL14060399A patent/IL140603A0/xx not_active IP Right Cessation
- 1999-07-02 ES ES99934560T patent/ES2183583T3/es not_active Expired - Lifetime
- 1999-07-02 EP EP99934560A patent/EP1093369B1/de not_active Expired - Lifetime
- 1999-07-02 ID IDW20010017A patent/ID27776A/id unknown
- 1999-07-02 SK SK11-2001A patent/SK284923B6/sk not_active IP Right Cessation
- 1999-07-02 CA CA002336833A patent/CA2336833C/en not_active Expired - Fee Related
- 1999-07-02 TR TR2001/00146T patent/TR200100146T2/xx unknown
- 1999-07-02 NZ NZ509729A patent/NZ509729A/xx unknown
- 1999-07-02 CN CNB998083038A patent/CN1230168C/zh not_active Expired - Fee Related
- 1999-07-02 AT AT99934560T patent/ATE228365T1/de not_active IP Right Cessation
- 1999-07-02 KR KR1020017000088A patent/KR100557692B1/ko not_active Expired - Fee Related
- 1999-07-02 PT PT99934560T patent/PT1093369E/pt unknown
- 1999-07-02 AU AU50303/99A patent/AU762128B2/en not_active Ceased
- 1999-07-02 BR BR9911768-1A patent/BR9911768A/pt not_active Application Discontinuation
- 1999-07-02 JP JP2000558802A patent/JP2002520273A/ja active Pending
- 1999-07-02 EE EEP200100014A patent/EE04296B1/xx not_active IP Right Cessation
- 1999-07-06 US US09/348,591 patent/US6255329B1/en not_active Expired - Fee Related
- 1999-07-06 TW TW088111454A patent/TW592698B/zh not_active IP Right Cessation
- 1999-07-07 AR ARP990103294A patent/AR019896A1/es unknown
- 1999-07-07 MY MYPI99002869A patent/MY117969A/en unknown
-
2001
- 2001-01-03 BG BG105112A patent/BG64972B1/bg unknown
- 2001-01-04 ZA ZA200100090A patent/ZA200100090B/en unknown
- 2001-01-05 NO NO20010064A patent/NO20010064L/no not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08504201A (ja) * | 1992-12-05 | 1996-05-07 | ベーリンガー インゲルハイム コマンディトゲゼルシャフト | 抗うつ作用を有する医薬組成物としての２‐アミノ‐６‐ｎ‐プロピル‐アミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールの使用 |
| JPH09110695A (ja) * | 1995-08-15 | 1997-04-28 | Chugai Pharmaceut Co Ltd | 不安神経症治療剤 |
| JPH11506472A (ja) * | 1996-03-29 | 1999-06-08 | ファイザー インク． | ５―ｈｔ１ａおよび／または５―ｈｔ１ｄ受容体の選択的（アンタ）アゴニストとしてのベンジル（イデン）―ラクタム誘導体、その調製法及びその使用法 |
Non-Patent Citations (1)
| Title |
|---|
| JPN6009054508, ＭＡＪ，Ｊ． ｅｔ ａｌ, "Ｔｈｅ ｂｅｈａｖｉｏｕｒａｌ ｅｆｆｅｃｔｓ ｏｆ ｐｒａｍｉｐｅｘｏｌｅ， ａ ｎｏｖｅｌ ｄｏｐａｍｉｎｅ ｒｅｃｅｐｔｏｒ ａｇｏｎｉｓｔ", Ｅｕｒ Ｊ Ｐｈａｒｍａｃｏｌ, 1997, Ｖｏｌ．３２４， Ｎｏ．１, ｐ．３１−３７ * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020516625A (ja) * | 2017-04-10 | 2020-06-11 | チェイス セラピューティクス コーポレイション | Ｎｋ１拮抗薬組み合わせおよびシヌクレイノパチーを治療する方法 |
| JP7271437B2 (ja) | 2017-04-10 | 2023-05-11 | チェイス セラピューティクス コーポレイション | Ｎｋ１拮抗薬組み合わせおよびシヌクレイノパチーを治療する方法 |
| JP2020526494A (ja) * | 2017-06-30 | 2020-08-31 | チェイス セラピューティクス コーポレイション | Ｎｋ−１アンタゴニスト組成物およびうつ病の処置における使用法 |
| JP7158425B2 (ja) | 2017-06-30 | 2022-10-21 | チェイス セラピューティクス コーポレイション | Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法 |
| US11813247B2 (en) | 2017-06-30 | 2023-11-14 | Chase Therapeutics Corporation | NK-1 antagonist compositions and methods for use in treating depression |
| US11813248B2 (en) | 2017-06-30 | 2023-11-14 | Chase Therapeutics Corporation | NK-1 antagonist compositions and methods for use in treating depression |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002520273A (ja) | 抗うつ効果を有する治療薬 | |
| US6667329B1 (en) | Agents with antidepressant action, containing pramipexol and second antidepressant | |
| JP2818303B2 (ja) | フィブロミアルギアの処置のためのセロトニンアンタゴニスト（５ｈｔ▲下３▼）の使用 | |
| EP0278821B1 (fr) | Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis | |
| US9238033B2 (en) | Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine | |
| JP2014196328A (ja) | ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤 | |
| WO2017041112A1 (en) | Ketamine and cytochrome p 450 inhibitor combinations | |
| JP2655706B2 (ja) | 抗パーキンソン病エルゴリン誘導体 | |
| KR930007252B1 (ko) | 우울증 치료용 약학조성물 | |
| JP2002531402A (ja) | 新規な医薬組成物 | |
| EP1965784A1 (fr) | Combinaison comprenant de la combretastatine et des agents anticancereux | |
| EP3664787B1 (en) | Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors | |
| US6391876B1 (en) | Reboxetine for treatment obsessive compulsive disorders and panic disorder | |
| JP2002524509A (ja) | 新規組成物 | |
| MXPA01001180A (es) | Metodos y composiciones para el tratamiento y la prevencion de abuso de sustancias empleando moclobemida. | |
| CA2453445C (fr) | Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides | |
| FR2641971A1 (fr) | Composition pharmaceutique antihypertensive associant le benazepril et un diuretique thiazidique | |
| JP2002524507A (ja) | 新規組成物 | |
| CN100355423C (zh) | 用于治疗肿瘤的包含血管抑制化合物和烷化剂的组合 | |
| JPH0827029A (ja) | ５ｈｔ１ 作動薬の新規医薬用途 | |
| MXPA00010025A (en) | New treatments for nervous disorders | |
| HK1135017A (en) | Combination preparations comprising slv308 and a l-dopa | |
| MXPA00012880A (en) | Agents with an antidepressive effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091022 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100325 |